Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
Clinical trial NCT05298813 · COMPLETED
Trial details
- NCT number
- NCT05298813
- Sponsor
- Immune Biosolutions Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-29
- Primary completion
- 2023-01-04
- Enrollment
- 162
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.